GHN Partnerships WG Webinar, June 30, 2023
Speaker: Dr. Venkataraman RadhakrishnanTopic: Chemotherapy-induced nausea and vomiting
Related Articles
Director of Research – Chennai, Tamil Nadu (IN)
Applications are invited for the post of Director of Research at Cancer Institute (WIA), Chennai, India.
Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study)
PURPOSE The effectiveness of a dexamethasone (DEX)-free regimen for chemotherapy-induced nausea and vomiting (CINV) prophylaxis in patients receiving highly emetogenic chemotherapy (HEC) is not known.…
Venkatraman Radhakrishnan: CTRT in locally advanced inoperable breast cancer – OncoDaily
Venkatraman Radhakrishnan: CTRT in locally advanced inoperable breast cancer / Breast Cancer, cancer, Concurrent chemoradiation, OncoDaily, Oncology,
Effect of Neoadjuvant Concurrent Chemoradiation on Operability and Survival in Locally Advanced Inoperable Breast Cancer
Inoperable locally advanced breast cancers (LABCs) are treated with neoadjuvant chemotherapy. We studied the use of neoadjuvant concurrent chemoradiation (NACCRT) in patients with inoperable LABC.
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting
Supportive Care in Cancer – This review is an update of the MASCC/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting…
